Φορτώνει......
How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies
In the last five years, everolimus has demonstrated efficacy in the treatment of neuroendocrine tumors (NETs) of different origins; its efficacy and safety were explored in the RADIANT trials, the last of which (RADIANT-4) has been recently published (December 2015). Overall, evidence collected from...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Oncotarget |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Impact Journals LLC
2016
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5190138/ https://ncbi.nlm.nih.gov/pubmed/27057638 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8601 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|